BridgeBio (BBIO) announced that Thomas Trimarchi has been appointed president and CFO of the company. He recently assumed the role of principal financial officer and will continue to lead the company’s FP&A and accounting operations. Brian Stephenson will depart from the company for personal reasons. Stephenson will continue to serve as a consultant to the company.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- KKR Genetic Dosorder L.P. announces sale of 6M shares of BridgeBio
- BridgeBio prices $575M convertible notes offering
- BridgeBio Pharma Strengthens Financial Position with Note Issuance
- BridgeBio price target raised to $46 from $45 at BofA
- Strong Launch and Strategic Initiatives Propel BridgeBio Pharma’s Growth Prospects